Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)

Exclusion Criteria

• •1.New York Heart Association (NYHA) Class II or greater heart failure;
• •2.Severe heart disease or discomfort, including but not limited to: High-risk uncontrolled arrhythmias, atrial tachycardia (heart rate\>100/min at rest), significant ventricular arrhythmias (ventricular arrhythmias) or higher, atrioventricular block (\[Mobitz 2\] or third-degree atrioventricular block); Angina pectoris that needs to be treated with anti-anginal medicine; Valvular heart disease with clinical significance; Electrocardiogram shows transmural myocardial infarction; Uncontrolled high blood pressure(eg: Systolic blood pressure\> 180 mmHg or diastolic blood pressure\> 100 mmHg);
• •3.Prior received neoadjuvant chemotherapy;
• •4.Severe systemic infection or other serious disease;
• •5.Allergies to chemotherapeutic drugs or their excipients or intolerant patients;
• •6.Other malignant tumors have been found in the past 5 years,except for cured cervical carcinoma in situ, non melanoma of the skin;
• •7.Childbearing age patients who are pregnant or lactation and refusing to take effective contraceptive measures during the trial;
• •8.Received any other test drug treatment or participated in other clinical trials at the same time;
• •9.Other conditions considered to be inappropriate to be enrolled by the investigator.